Nephrology ·
FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant

Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Food and Drug Administration (FDA) on Nov. 13 approved Gazyva (obinutuzumab), the first drug specifically for primary membranous nephropathy, after 36% complete remission versus 6% with tacrolimus.
A randomized trial found dapagliflozin improved eGFR slope in heart transplant recipients, and pegcetacoplan kept proteinuria down through one year in C3 glomerulopathy.
THE DETAILS
- FDA Nov 13, 2026The Food and Drug Administration (FDA) approved obinutuzumab on Nov. 13 for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. In the phase 3 open-label MAJESTY trial of 142 adults randomized to obinutuzumab or tacrolimus, complete remission at week 104 was 36% versus 6%. The label carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy, and infusion-related reactions and upper respiratory tract infection were the most common side effects, according to the FDA.Source: FDA
- Research Nov 8, 2026In a double-blind, placebo-controlled trial at six heart transplant centers in Northern Europe, published Nov. 8 in Circulation, eGFR changed by 2.0 mL/min/1.73 m2 with dapagliflozin and 0.3 with placebo from two weeks to 12 months, a between-group difference of 1.7 (95% CI 0.1 to 3.3; P = .03). The authors said dapagliflozin improved the eGFR slope over the treatment period.Source: Circulation
- Research Nov 13, 2026In a prespecified exploratory analysis of the open-label period of the phase 3 VALIANT trial, published Nov. 13 in the Journal of the American Society of Nephrology, patients given pegcetacoplan throughout had a 67.2% reduction from baseline in urine protein-to-creatinine ratio at week 52. Fifty-nine patients first given pegcetacoplan and 55 first given placebo completed the open-label period. The authors said the results show sustained proteinuria reduction and eGFR stabilization after one year.
- Research Nov 13, 2026In a target trial emulation of Veterans Health Administration data published Nov. 13 in the Journal of the American Society of Nephrology, adding a calcium channel blocker instead of a thiazide was associated with more cardiovascular events (adjusted hazard ratio 1.18, 95% CI 1.15 to 1.22), as were beta-blockers (1.63) and loop diuretics (1.97). Composite kidney outcomes were also higher with calcium channel blockers (adjusted hazard ratio 1.42, 95% CI 1.33 to 1.52) and loop diuretics (1.98). The study is observational.
- Guidelines Nov 14, 2026A report of a 2025 scientific workshop sponsored by the National Kidney Foundation, published Nov. 14 in the American Journal of Kidney Diseases, concluded that measurement of urinary albumin concentration should in general be preferred when determining urinary protein excretion in future clinical practice and trials. The report said urinary albumin assays are expected to be internationally standardized beginning in 2027 and cited a moderately stronger association with clinical outcomes for albumin.
The weekly innovation roundup for nephrology, published every Sunday for the week before; every item links to its sources. Latest nephrology news · All specialties